Frespaciguat

N/A

Report date: 2025/12/02 15:16:18
NME

Base Information

Drug NameFrespaciguat
Drug Alias NameMK-5475
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSoluble guanylate cyclase stimulants
TargetsSoluble guanylate cyclase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)HypoxiaPulmonary Disease, Chronic Obstructive +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[27] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme CorpMerck Sharp & Dohme LLCMSD R&D（China）Co Ltd
Inactive CompaniesN/A
Active IndicationsPulmonary Disease, Chronic ObstructivePulmonary Arterial HypertensionHypertension, Pulmonary
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)HypoxiaPneumonia

Other Information

ATC CodeN/A
Related LinksN/A